Sign In
Buy EYEN
$7.56
+0 (+0%)
At Close: Jan 16, 2026
Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings
02:04pm, Wednesday, 18'th Jun 2025
NEW YORK , June 18, 2025 /PRNewswire/ -- Chardan, a leading global investment banking and advisory firm, today announced an expansion into the digital asset sector, advising on and structuring a seri
EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy
Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy
02:55pm, Tuesday, 17'th Jun 2025
Announces private placement EYEN to become first U.S.-based publicly listed company to hold HYPE in its treasury Hyunsu Jung appointed Chief Investment Officer and Board Member LAGUNA HILLS, Calif., J
Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent
Eyenovia Provides Development Update on Optejet User Filled Device (UFD)
07:00am, Thursday, 10'th Apr 2025
On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq
07:00am, Thursday, 20'th Mar 2025
Combination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol ® water-free drug delivery technology for glaucoma with Eyenovia's Optejet ® device platfor
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements
07:00am, Wednesday, 26'th Feb 2025
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Opt
Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs Amendment provide
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device
07:00am, Wednesday, 05'th Feb 2025
Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this
Eyenovia Announces 1-for-80 Reverse Stock Split
04:05pm, Tuesday, 28'th Jan 2025
Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives Revers
Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders m
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives
07:00am, Monday, 06'th Jan 2025
Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% Company concurrently focused on completing development of t
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
08:00am, Friday, 06'th Dec 2024
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products lev
Eyenovia Provides Update on Restructuring Efforts
07:00am, Friday, 22'nd Nov 2024
Avenue Capital agrees to Company's deferral of principal and interest payments on its outstanding debt until the end of February 2025
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
10:50am, Monday, 18'th Nov 2024
EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.
